Prescription Drugs: Capping Out-of-Pocket Costs
The Fair Prescription Pricing Act of 2026 is currently in the early stages of the legislative process. It was sent to three different House committees on August 20, 2026, and has not moved since that date. These committees must review the bill before it can proceed to a full vote.
This bill was recently introduced and has not yet gained the broad support or committee approval needed to move forward quickly in the House.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Small businesses that sponsor group health plans for employees could see insurers adjust premiums to offset the new limits on drug cost sharing, since insurers can no longer pass certain drug costs onto employees through copays and deductibles. This could raise plan costs for employers even as it lowers costs for their workers at the pharmacy.
“a group health plan, and a health insurance issuer offering group or individual health insurance coverage, may not impose cost sharing”
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes, news coverage, or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Fair Prescription Pricing Act of 2026
Analysis generated by AI. Always verify with official sources.